ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025

Reuters09-24

ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025

ESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right $(CVR)$ that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2569777136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569777136","market":"us","top_or_hot":-1,"title":"ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-24 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPIX","symbol_name":"ESSA Pharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL53Zm9:1","article_id":"2569777136","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569777136","pubTimestamp":1758708052,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right  that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPIX":"ESSA Pharma Inc.","BK4139":"生物科技","XOMA":"标记临床研究"},"translate_title":"ESSA Pharma更新XenoTherapeutics交易条款，降低股东派息并将特别会议推迟至2025年10月","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPIX":0.9,"XOMA":0.9},"content_text":"ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    \n\nESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right $(CVR)$ that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569777136","isCrawlerRequest":true}